Pfizer's experimental lung cancer drug, which was hoped to replace a widely used chemotherapy in one of the most common forms of lung cancer, has fallen short in a clinical trial. This development comes as the Ebola outbreak in eastern Congo continues to worsen, with confirmed cases reaching 1,003 and 254 deaths reported. Meanwhile, a new trial is set to begin in the UK to examine the risks and benefits of puberty blockers for gender-questioning children.
Why It Matters
The failure of Pfizer's lung cancer drug is a significant setback for patients with non-small cell lung cancer, who are in urgent need of new treatment options. The Ebola outbreak in Congo continues to pose a major public health threat, and efforts to contain it are being hindered by challenges in tracing contacts of patients. The new trial on puberty blockers is a crucial step in understanding the risks and benefits of these drugs for gender-questioning children.
What Experts Say
"I am absolutely convinced that more children will be harmed if we don't do the trial than if we do." — Dr. Hilary Cass, author of a landmark review on gender medicine for children.
Key Numbers
- 11: Age of the youngest children who may be recruited for the puberty blockers trial.
Background
The Ebola outbreak in Congo began in August 2018 and has been ongoing for over a year. The World Health Organization has declared it a Public Health Emergency of International Concern. Pfizer's experimental lung cancer drug was hoped to be a major breakthrough in the treatment of non-small cell lung cancer, but its failure in clinical trials is a significant setback.
What Comes Next
The new trial on puberty blockers will provide crucial information on the risks and benefits of these drugs for gender-questioning children. The Ebola outbreak in Congo continues to require a coordinated international response to contain it. The failure of Pfizer's lung cancer drug highlights the need for continued investment in cancer research to develop new and effective treatments.
Key Facts
- Who: Pfizer, Dr. Hilary Cass, World Health Organization.
- What: Experimental lung cancer drug, Ebola outbreak, puberty blockers trial.
- When: Ongoing Ebola outbreak, new trial set to begin in the UK.
- Where: Congo, UK.
- Impact: Significant setback for lung cancer patients, major public health threat from Ebola, crucial information on puberty blockers.